exhibit 10. 3 transfer and termination agreement dated may 6, 2015 ( " effective date " ) parties : sucampo ag, incorporated and registered in switzerland with offices at baarerstrasse 22, ch - 6300 zug, switzerland and its affiliates ( " sucampo " ), and r - tech ueno, ltd. incorporated and registered in japan with offices at 10f, nbf hibiya building, 1 - 1 - 7, uchisaiwaicho, chiyoda - ku, tokyo 100 - 0011 ( " r - tech " ). hereinafter referred to as " party " and together, the " parties ". preamble : whereas, an affiliate of sucampo ag, sucampo pharma americas, inc. and r - tech entered into the unoprostone nda transfer, patent and know - how licensing, and data sharing agreement effective april 23, 2009 ( the " 2009 license agreement " ) granting an exclusive license to certain patents related to unoprostone ( as defined below ), and sucampo pharma americas, inc. subsequently assigned the 2009 license agreement to sucampo ag effective september 30, 2011, which was accepted by r - tech on september 28, 2011 ; and whereas, sucampo manufacturing & research ag and r - tech entered into the exclusive license for development and commercialization of unoprostone dated march 22, 2011 ( the “ 2011 license agreement ” ) and sucampo manufacturing & research ag, subsequently as a result of merger effective may 24, 2011, assigned the 2011 license agreement to sucampo ag ; and whereas, sucampo ag and r - tech entered into the quality assurance agreement dated august 23, 2012 ; and whereas, sucampo ag and r - tech entered into the safety data exchange agreement dated may 20, 2013 ; and whereas, r - tech provided a draft press release which r - tech subsequently issued on march 9, 2015 that caused sucampo to advise r - tech that it would no longer develop unoprostone ; and whereas, sucampo advised r - tech in writing on march 9, 2015 that it would return the 2009 license agreement and 2011 license agreement ( collectively, the “ license rights ” ) to r - tech so that r - tech could find another partner to develop and commercialize unoprostone ; and whereas, the parties have agreed to work together in good faith to terminate the agreements listed above